Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions
Open Access
- 13 July 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (29), 1878-1891
- https://doi.org/10.1093/eurheartj/ehv333
Abstract
Mitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous aetiologies, including primary (organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology, and secondary (functional) MR, which is principally caused by global or regional left ventricular remodelling and/or severe left atrial dilation. Diagnosis and optimal management of MR requires integration of valve disease and heart failure specialists, MV cardiac surgeons, interventional cardiologists with expertise in structural heart disease, and imaging experts. The introduction of trans- catheter MV therapies has highlighted the need for a consensus approach to pragmatic clinical trial design and uniform endpoint definitions to evaluate outcomes in patients with MR. The Mitral Valve Academic Research Consortium is a collaboration between leading academic research organizations and physician-scientists specializing in MV disease from the United States and Europe. Three in-person meetings were held in Virginia and New York during which 44 heart failure, valve, and imaging experts, MV surgeons and interventional cardiologists, clinical trial specialists and statisticians, and representatives from the U.S. Food and Drug Administration considered all aspects of MV pathophysiology, prognosis, and therapies, culminating in a 2-part document describing consensus recommendations for clinical trial design (Part 1) and endpoint definitions (Part 2) to guide evaluation of transcatheter and surgical therapies for MR. The adoption of these recommendations will afford robustness and consistency in the comparative effectiveness evaluation of new devices and approaches to treat MR. These principles may be useful for regulatory assessment of new transcatheter MV devices, as well as for monitoring local and regional outcomes to guide quality improvement initiatives.Keywords
This publication has 68 references indexed in Scilit:
- Percutaneous Mitral Valve Interventions in the Real World: Early and 1-Year Results From the ACCESS-EU, A Prospective, Multicenter, Nonrandomized Post-Approval Study of the MitraClip Therapy in EuropeJournal of the American College of Cardiology, 2013
- An Updated Definition of Stroke for the 21st CenturyStroke, 2013
- Heart Disease and Stroke Statistics—2013 UpdateCirculation, 2013
- Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research ConsortiumEuropean Heart Journal, 2010
- Recent National Trends in Readmission Rates After Heart Failure HospitalizationCirculation: Heart Failure, 2010
- Rehospitalizations among Patients in the Medicare Fee-for-Service ProgramThe New England Journal of Medicine, 2009
- Cerebral Ischemic Lesions on Diffusion-Weighted Imaging Are Associated With Neurocognitive Decline After Cardiac SurgeryStroke, 2008
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findingsAmerican Journal Of Medicine, 1994
- A critical appraisal of stroke evaluation and rating scales.Stroke, 1991